DRUG · Unmapped registry intervention
SHR-A1811 + Adebrelimab
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
NCT07281209
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
NSCLCverified · MONDO: non-small cell lung carcinoma
Interventions
Sponsors & collaborators
Shanghai Chest Hospitallead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07281209 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.